P
Description
PharmNovo is a Swedish clinical-stage pharmaceutical company headquartered at Medicon Village (Lund), founded in 2008, focused on developing safe and effective drugs for neuropathic pain. Its lead candidate PN6047 is a first-in-class Delta Opioid Receptor Agonist (DORA) without addictive potential: acts without activating the mu-opioid receptor, avoiding conventional opioid risks. Phase I completed with positive safety profile. Phase IIa approved in Spain.